Molecular profiling and computational network analysis of TAZ-mediated mammary tumorigenesis identifies actionable therapeutic targets
暂无分享,去创建一个
Maxime Blijlevens | N. Yang | C. Frangou | K. Wilson | Jianmin Zhang | N. Nowak | H. Shen | Jin Guo | Ying-Wei Li | Kayla E. Wilson
[1] C. Gialeli,et al. PDGF/PDGFR signaling and targeting in cancer growth and progression: Focus on tumor microenvironment and cancer-associated fibroblasts. , 2014, Current pharmaceutical design.
[2] Jianmin Wu,et al. Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling , 2014, Cell.
[3] G. Halder,et al. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment , 2013, Nature Reviews Drug Discovery.
[4] K. Guan,et al. Regulation of the Hippo pathway and implications for anticancer drug development. , 2013, Trends in pharmacological sciences.
[5] Marc L. Mendillo,et al. A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. , 2013, Cancer cell.
[6] N. Yang,et al. PTPN14 interacts with and negatively regulates the oncogenic function of YAP , 2013, Oncogene.
[7] David M. Thomas,et al. The Hippo pathway and human cancer , 2013, Nature Reviews Cancer.
[8] K. Guan,et al. The Hippo pathway: regulators and regulations. , 2013, Genes & development.
[9] Jeffrey T. Chang,et al. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. , 2013, Cancer research.
[10] Sridhar Ramaswamy,et al. Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition , 2013, Science.
[11] K. Guan,et al. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. , 2012, Seminars in cell & developmental biology.
[12] N. Yang,et al. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin , 2012, Cell cycle.
[13] J. Visvader,et al. Cancer stem cells: current status and evolving complexities. , 2012, Cell stem cell.
[14] Peter Dirks,et al. Cancer stem cells: an evolving concept , 2012, Nature Reviews Cancer.
[15] S. Bicciato,et al. The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.
[16] G. M. Rudakova,et al. α-Catenin Is a Tumor Suppressor That Controls Cell Accumulation by Regulating the Localization and Activity of the Transcriptional Coactivator Yap1 , 2011, Science Signaling.
[17] Antonio Gnoni,et al. Dasatinib: an anti-tumour agent via Src inhibition. , 2011, Current drug targets.
[18] A. Pobbati,et al. Hippo Pathway-independent Restriction of TAZ and YAP by Angiomotin* , 2011, The Journal of Biological Chemistry.
[19] Junjie Chen,et al. Angiomotin-like Proteins Associate with and Negatively Regulate YAP1* , 2010, The Journal of Biological Chemistry.
[20] Gary D Bader,et al. Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation , 2010, PloS one.
[21] D. Pan,et al. The hippo signaling pathway in development and cancer. , 2010, Developmental cell.
[22] Zhengyu Zha,et al. The Hippo Tumor Pathway Promotes TAZ Degradation by Phosphorylating a Phosphodegron and Recruiting the SCFβ-TrCP E3 Ligase* , 2010, The Journal of Biological Chemistry.
[23] L. Stein,et al. A human functional protein interaction network and its application to cancer data analysis , 2010, Genome Biology.
[24] Li Li,et al. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. , 2010, Genes & development.
[25] Justin C. Grindley,et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery , 2009, Nature Reviews Drug Discovery.
[26] Eric S. Lander,et al. Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.
[27] Debra L Winkeljohn. Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.
[28] A. Barabasi,et al. An empirical framework for binary interactome mapping , 2008, Nature Methods.
[29] M. Yaffe,et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal , 2008, Nature Cell Biology.
[30] Max S Wicha,et al. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Wenjun Guo,et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.
[32] Jianmin Zhang,et al. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. , 2008, Cancer research.
[33] Kevin J. Cheung,et al. Tumor Suppressor LATS1 Is a Negative Regulator of Oncogene YAP* , 2008, Journal of Biological Chemistry.
[34] Zhengyu Zha,et al. TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo Pathway , 2008, Molecular and Cellular Biology.
[35] Brad T. Sherman,et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.
[36] Jayanta Debnath,et al. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.
[37] S. Morrison,et al. Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[38] T. Jacks,et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. , 1998, Genes & development.
[39] S. Aaronson,et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. , 1973, Journal of the National Cancer Institute.
[40] J.,et al. The New England Journal of Medicine , 2012 .
[41] K. Guan,et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. , 2011, Genes & development.
[42] N. Maitland,et al. Cancer stem cells, models of study and implications of therapy resistance mechanisms. , 2011, Advances in experimental medicine and biology.